en Cardiovascular Physiology/Pharmacology Cardiovascular Physiology/Pharmacology Experimental research article Experimental research article <p>Introduction: Ganoderma lucidum (G. lucidum), a medicinal mushroom, exerts protective effects on cardiovascular diseases but, it&rsquo;s effect in isoproterenol-induced heart failure has not been studied. Therefore, the aim of the present study was whether G. lucidum has protective effects in isoproterenol-induced heart failure.<br /> <strong>Methods:</strong> Thirty male Wistar rats were assigned into five groups (n=6) of control, heart failure (HF) and G. lucidum (50, 100 and 200mg/kg). For induction of HF in rats, isoproterenol (5mg/ kg) was injected subcutaneously for two weeks. In G. lucidum treated groups, G. lucidum was orally gavaged for three weeks and on day 8 isoproterenol was injected for two weeks. Then, Electrocardiogram pattern and cardiodynamic parameters, as well as myeloperoxidase activity, malondialdehyde level, cardiac remodeling and apoptosis were studied.<br /> <strong>Results:</strong> G. lucidum improved hemodynamic factors such as mean arterial blood pressure as well as electrocardiogram pattern. Pre-treatment with G. lucidum also decreased myeloperoxidase activity, malondialdehyde level and apoptosis in cardiac tissue. Histopathologic results showed a decrease in cardiac necrosis and fibrosis. However, it had no significant effect on cardiac hypertrophy.<br /> <strong>Conclusion:</strong> Our results show that pre-treatment with G. lucidum demonstrates protective effects against HF, and thereby suggest that G. lucidum can be considered as a possible clinical use for preventive and adjuvant treatment in heart failure.<span style="font-size:11pt"><span style="line-height:200%"><span style="text-autospace:none"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="line-height:200%"><span style="font-family:"Times New Roman",serif"></span></span></span></span></span></span></span></p> Ganoderma lucidum, Heart failure, Isoproterenol, Inflammation, Oxidative stress, Apoptosis 271 282 http://ppj.phypha.ir/browse.php?a_code=A-10-1741-2&slc_lang=en&sid=1 Monireh Seiiedy monirseiiedy72@gmail.com 3200319475328460033191 000000030602230X No Department of Pharmacology and Toxicology, School of Pharmacy, Urmia University of Medical Sciences, Urmia, Iran Chiman Salehi salehichiman@gmail.com 3200319475328460033192 000000030602230X No Department of Pharmacology and Toxicology, School of Pharmacy, Urmia University of Medical Sciences, Urmia, Iran Morteza Ghasemnejad Berengi morteza.ghasemnejad@yahoo.com 3200319475328460033193 0000000156729202 No Department of Pharmacology and Toxicology, School of Pharmacy, Urmia University of Medical Sciences, Urmia, Iran mojtaba karimipour mojtaba_karimipour@yahoo.com 3200319475328460033194 0000000228342892 No Department of Anatomy, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran Jafar Rezaie j.rezaie88@gmail.com 3200319475328460033195 0000000181753730 No Solid Tumor Research Center, Cellular and Molecular Medicine Institute, Urmia University of Medical Sciences, Urmia, Iran Shabnam Babataheri shabnambabataheri90@gmail.com 3200319475328460033196 000000030602230X No 1Experimental and Applied Pharmaceutical Research Center, Urmia University of Medical Sciences, Urmia, Iran2Department of Pharmacology and Toxicology, School of Pharmacy, Urmia University of Medical Sciences, Urmia, Iran Hamid Soraya hamid_soraya2000@yahoo.com 3200319475328460033197 000000030602230X Yes Experimental and Applied Pharmaceutical Research Center, Urmia University of Medical Sciences, Urmia, IranDepartment of Pharmacology and Toxicology, School of Pharmacy, Urmia University of Medical Sciences, Urmia, Iran